The publication of this promotional infographic was supported and funded by argenx. This content is intended for healthcare professionals in the EU, Norway, Iceland, and Liechtenstein ONLY.
Efgartigimod▼ SmPC and Adverse Event Reporting
Prescribing information can be found here. Adverse event reporting details can be found here. These details are also available within the infographic. Product indications can be found at the bottom of the page.
Footnote:
Efgartigimod is indicated in the EU as an add-on to standard therapy for the treatment of adult patients with gMG who are AChR antibody–positive.
This medicinal product is subject to additional monitoring. This will allow quick identification of new safety information. Healthcare professionals are asked to report any suspected adverse reactions here.
EU-VYV-25-00026 | June 2025
